- Home
- GENI vs RAPP Comparison
GENI vs RAPP Comparison
Compare GENI & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GENI | RAPP |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GENI | RAPP |
|---|---|---|
| Price | $6.91 | $41.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | $12.75 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 4.8M | 354.0K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.00 | N/A |
| Revenue Next Year | $20.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $13.64 |
| 52 Week High | $13.73 | $44.28 |
Technical Indicators
Market Signals| Indicator | GENI | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 51.35 |
| Support Level | $5.55 | $38.55 |
| Resistance Level | $6.95 | $43.89 |
| Average True Range (ATR) | 0.38 | 2.43 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 59.55 | 42.93 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.